Appendix 4C - Q4 FY23 Quarterly Cash Flow Report Highlights: ATH434-201 Phase 2 study on track to complete enrollment in Q3 2023 with top-line data expected by the end of 2024 in individuals with Multiple System Atrophy

Appendix 4C - Q4 FY23

Quarterly Cash Flow Report

AUSTRALIA AND SAN FRANCISCO, USA - 31 July 2023. Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity"

or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases,

releases its Appendix 4C Quarterly Cash Flow Report and update on company activities for the quarter ending 30 June 2023 (Q4 FY23).

"The last several months

have been extremely productive for Alterity as we hit several milestones and made significant progress advancing ATH434," said David

Stamler, M.D., Chief Executive Officer, Alterity. "With the clearance by the Data Monitoring Committee to continue the ATH434-201

trial as planned and the enthusiasm for the trial from physicians around the world, the trial remains on track to complete enrollment

in the third quarter of 2023 with top-line data expected by the end of 2024."

Dr. Stamler, continued, "We

also initiated a second Phase 2 study, ATH434-202, in participants with more advanced MSA. Importantly, this Biomarker study gives us

the opportunity to get an early indication of efficacy before the ATH434-201 Phase 2 study reads out. Individuals with more advanced MSA

may also benefit from ATH434 and measuring key biomarkers will permit us to evaluate drug activity in this population. The data derived

from the Biomarker study have the potential to accelerate the overall development program."

"An important element of

our ATH434-201 trial is the use of wearable sensors to determine the impact of ATH434 on motor impairment and gait stability. During the

quarter, data from the bioMUSE natural history study reinforced this measure by showing that wearable sensors can be used to assess disease

progression that may not be captured by neurological examination," concluded Dr. Stamler.

The Company's cash position

on 30 June 2023 was A$15.8M with operating cash outflows for the quarter of A$6.2M. The company anticipates the cash position will be

boosted in the coming weeks with the receipt of the A$4.7M R&D Tax incentive for the 2022 fiscal year.

Operational Activities

ATH434-201 Phase 2 Clinical

Subsequent to the quarter, on 26

July, Alterity announced that the independent Data Monitoring Committee (DMC) for the ATH434-201 Phase 2 study recommended the trial continue

as planned. The DMC conducted a prespecified review of unblinded clinical data from an initial cohort of study participants. The DMC expressed

no concerns about safety and recommended that the study continue without modification.

This randomized, double blind,

placebo controlled clinical trial continues to progress with participants in both Australia and the United Kingdom now being treated.

The trial is enrolling participants with early stage MSA at over 15 sites in three regions - Australia/New Zealand, the United States,

and Europe. The trial is being well received by physicians across the board with feedback positive as they implement Alterity's

state of the art methods to diagnose and track the disease.

ATH434-202 Phase 2 Clinical

initiated enrollment in a second Phase 2 trial of ATH434 during the quarter in participants with MSA. This open label, single arm study,

entitled "A Biomarker Study of ATH434 in participants with MSA" (ATH434-202), allows Alterity to evaluate the effect of ATH434

on a MSA population more advanced than that being investigated in the randomized study. The design of the Biomarker study will allow the

Company to perform interim analyses of biomarker data during conduct, with potential to provide early indications of efficacy before the

randomized study reads out.

The key aim of the study is to

assess the efficacy of ATH434 on objective biomarkers that measure target engagement and are relevant to the underlying pathology of disease.

Clinical measures important in MSA will also be assessed.

Promising wearable sensor data

from the bioMUSE Natural History Study

quarter, analysis from the Biomarkers of Progression in Multiple System Atrophy (bioMUSE) natural history study demonstrated that wearable

sensors can quantify motor impairment in individuals with MSA that is not captured by neurological examination. This means that wearable

sensors can be used to assess disease progression and inform clinical trials. These data were presented at the American Academy of Neurology

Annual Meeting. As a result of the study, Alterity has incorporated wearable sensor data into its Phase 2 clinical trial for ATH434 as

one of its secondary endpoints to determine the effect of treatment on gait parameters.

The ongoing bioMUSE study will

continue to provide vital information on early stage MSA, inform the selection of biomarkers suitable to evaluate target engagement and

preliminary efficacy, and deliver clinical data to characterize disease progression in a population that mirrors those being studied in

Alterity's ATH434-201 trial.

About Alterity Therapeutics

Alterity Therapeutics is a clinical

stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company's

lead asset, ATH434, has the potential to treat various Parkinsonian disorders. Alterity also has a broad drug discovery platform generating

patentable chemical compounds to intercede in disease processes. The Company is based in Melbourne, Australia, and San Francisco, California,

USA. For further information please visit the Company's web site at www.alteritytherapeutics.com.

Authorisation & Additional information

This announcement was authorised by David Stamler, CEO

of Alterity Therapeutics Limited.

Investor and Media Contacts:

Forward Looking Statements

This press release contains

"forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities

Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as "expects," "intends,"

"hopes," "anticipates," "believes," "could," "may," "evidences" and "estimates,"

and other similar expressions, but these words are not the exclusive means of identifying such statements.

Important factors that could

cause actual results to differ materially from those indicated by such forward- looking statements are described in the sections titled

"Risk Factors" in the Company's filings with the SEC, including its most recent Annual Report on Form 20-F as well as

reports on Form 6-K, including, but not limited to the following: statements relating to the Company's drug development program, including,

but not limited to the initiation, progress and outcomes of clinical trials of the Company's drug development program, including, but

not limited to, ATH434, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including,

but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory

approval, production and marketing of the Company's drug components, including, but not limited to, ATH434, the ability of the Company

to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's

drug compounds, including, but not limited to, ATH434, that could slow or prevent products coming to market, the uncertainty of obtaining

patent protection for the Company's intellectual property or trade secrets, the uncertainty of successfully enforcing the Company's

patent rights and the uncertainty of the Company freedom to operate.

Any forward-looking statement

made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is

made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time

to time, whether as a result of new information, future developments or otherwise.

Quarterly cash flow report

for entities subject to Listing Rule 4.7B

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Quarterly cash flow report for entities subject to Listing Rule 4.7B